Latest Interventional cardiology Stories
TORONTO, Jan. 8, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, declines in procedure volumes in the United States interventional cardiology (IC) market will lead to a long-term contraction. As a result of the procedure volume decline, coupled with increasing cost sensitivity, this market will show a steady contraction from a value of just under $2.5 billion in 2012 to just under $2 billion by 2017....
PLEASANTON, Calif., Jan. 7, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support (MCS) therapies to save, support and restore failing hearts, today announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) to commence the REVIVE-IT study utilizing the HeartMate II® Left Ventricular Assist System. REVIVE-IT (Randomized Evaluation of VAD InterVEntion before...
TEL AVIV, Israel, January 4, 2013 /PRNewswire/ -- InspireMD, Inc. (OTC: NSPRD) ("InspireMD" or the "Company") appointed Alan W. Milinazzo President, Chief Executive Officer, and a member of the board, effective January 3, 2013. He replaces Ofir Paz who previously announced his intention to step down as Chief Executive Officer in September 2012 once a successor was named. Mr. Paz will continue to serve as a director. Mr. Milinazzo brings fifteen years of experience in...
FRAMINGHAM, Mass. and SYDNEY, Australia, Jan. 3, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 31(st) Annual J.P. Morgan Healthcare Conference at 10:30 a.m. Pacific Standard Time (1:30 p.m. EST) on Monday, January 7. The conference is...
ABBOTT PARK, Ill., Jan. 3, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the XIENCE Xpedition((TM)) Everolimus Eluting Coronary Stent System received U.S. Food and Drug Administration (FDA) approval and is launching immediately in the United States, providing physicians with a next-generation technology with the largest size matrix in the U.S. market. XIENCE Xpedition features a new stent delivery system designed to optimize deliverability, particularly in...
PLEASANTON, Calif., Jan. 3, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the 31(st) Annual J.P. Morgan Healthcare Conference on Monday, January 7. Gary F. Burbach, President and Chief Executive Officer, will provide an update on the company, beginning at 8:00 a.m., Pacific Standard Time (11:00 a.m., Eastern...
NEW YORK, Jan. 2, 2013 /PRNewswire/ -- The FREEDOM trial, the first long-term, comparative study of its kind exclusively for patients with diabetes and advanced multivessel coronary artery disease (CAD) revealed that diabetics with CAD live longer, and are less likely to suffer a non-fatal heart attack, when treated with bypass surgery instead of drug-eluting stents (DES), tiny, medicine-coated mesh tubes that prop open clogged arteries. The findings were presented in the 2012...
The Helmsley Charitable Trust funds revolutionary robotic heart equipment at Sanford Sioux Falls, SD and Aberdeen, SD (PRWEB) December 17, 2012 Sanford Health announced today it has received $2.4m in funding from The Leona M. and Harry B. Helmsley Charitable Trust to advance heart care for the region. The grant will support the purchase and installation of the only Food and Drug Administration (FDA) cleared robotic-assisted technology to aid interventional cardiologists in placing stents...
PLEASANTON, Calif., Dec. 11, 2012 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that the company has received approval from Japan's Ministry of Health, Labour and Welfare to market HeartMate II®( )as a Bridge-to-Transplantation therapy for patients suffering from advanced heart failure. "Approval in Japan marks a significant milestone in...
PLEASANTON, Calif., Dec. 10, 2012 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Oppenheimer 23(rd) Annual Healthcare Conference on Wednesday, December 12. Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company beginning at 10:35 a.m., Eastern Standard Time (7:35 a.m., Pacific...
